News: Valeant Pharmaceuticals International Inc (VRX.N)


VRX.N on New York Stock Exchange

85.11USD
10 Jun 2013
Price Change (% chg)

$-0.48 (-0.56%)
Prev Close
$85.59
Open
$85.94
Day's High
$85.95
Day's Low
$84.39
Volume
163,843
Avg. Vol
283,868
52-wk High
$96.25
52-wk Low
$42.47

Search Stocks
Select another date:

Tue, Jun 18 2013

Valeant Pharma to launch $9.3 billion acquisition financing

NEW YORK - Valeant Pharmaceuticals has set a bank meeting for Wednesday to launch a $9.3 billion financing package backing the company's $8.7 billion acquisition of Bausch & Lomb , sources told Thomson Reuters LPC.

Continue Reading

RLPC: Valeant Pharma to launch $9.3B acq. financing

NEW YORK, June 18 - Valeant Pharmaceuticals has set a bank meeting for Wednesday to launch a $9.3 billion financing package backing the company's $8.7 billion acquisition of Bausch & Lomb, sources told Thomson Reuters LPC.

Valeant abandons bid for Serbia's Galenika

* Galenika needs 50 million euro of additional capital in 2013

EU agency calls for curbs on GSK, Valeant epilepsy drug

LONDON - Use of an epilepsy drug developed by GlaxoSmithKline and Valeant Pharmaceuticals should be restricted to patients for whom other anti-epileptic medicines have proved inadequate or not tolerated, EU regulators said on Friday.

Serbia extends Galenika sale until June 14 - Finance Ministry

BELGRADE, May 30 - Serbia on Thursday extended for another two weeks a deadline for bids for its indebted, state-run drugmaker Galenika Pharmaceuticals because only one potential partner has come forward.

Valeant says FDA denies approval to nail infection drug

May 28 - Canada drugmaker Valeant Pharmaceuticals International said on Tuesday that the U.S. Food and Drug Administration denied approval for its drug to treat onychomycosis, a fungal infection of the nail.

CANADA STOCKS-Valeant and gold miners help TSX rise in low-volume trade

* TSX ends up 29.15 points, or 0.23 percent, at 12,696.37 * Valeant surges after move to buy Bausch & Lomb * Gold shares climb after bullion price gains By Alastair Sharp TORONTO, May 27 - Shares in a pharmaceutical company making a big buy surged for a second straight session and the rising price of gold helped beaten-down miners bounce higher in low-volume trade on Canada's main stock index on Monday. Valeant Pharmaceuticals International hit an all-time high and

CANADA STOCKS-TSX ends up as Valeant and gold miners provide boost

TORONTO, May 27 - The main Canadian stock index ended higher on Monday in low volume trade, as investors cheered a takeover bid from Valeant Pharmaceuticals International Inc and a rise in the price of gold helped beaten-down miners of the precious metal. The Toronto Stock Exchange's S&P/TSX composite index unofficially closed up 29.15 points, or 0.23 percent, at 12,696.37 points.

Drugmaker Valeant to buy Bausch & Lomb for $8.7 billion

TORONTO/WINNIPEG, Manitoba - Valeant Pharmaceuticals International said on Monday it agreed to buy Bausch & Lomb Holdings Inc from Warburg Pincus LLC for $8.7 billion, a cash deal set to vault the Canadian company into the upper ranks of the global pharmaceutical sector.

UPDATE 3-Canada drugmaker Valeant to buy Bausch & Lomb for $8.7 billion

* To acquire Bausch & Lomb in all cash deal * Deal to be financed via debt and equity offering * Deal expected to immediately boost Valeant's cash EPS * Valeant shares hit all-time high in Toronto By Euan Rocha and Rod Nickel TORONTO/WINNIPEG, Manitoba, May 27 - Valeant Pharmaceuticals International said on Monday it agreed to buy Bausch & Lomb Holdings Inc from Warburg Pincus LLC for $8.7 billion, a cash deal set to vault the Canadian company into the upper ranks

Select another date:

Market Views

» More VRX.N Market Views

Press Releases

Search Stocks